2D-QSAR and HQSAR of the inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with N-(4-oxo-1(4H)-naphthalenylidene) benzenesulfonamide analogues

Archives of Pharmacal Research

Volumn 30, Issue 8, 2007, Pages 976-983

  Myung, Pyung Keun ^a   Sung, Nack Do ^a  

^a Chungnam National University   (South Korea)

Author keywords

2D QSAR HQSAR analysis; Immunomodulation agents; Inhibition of calcineurin NFAT signaling; N (4 oxo 1(4H) naphthalenylidene) benzenesulfonamides

Indexed keywords

CALCINEURIN; IMMUNOLOGIC FACTOR; N (4 OXO 1(4H) NAPHTHALENYLIDENE)BENZENESULFONAMIDE; N-(4-OXO-1(4H)-NAPHTHALENYLIDENE)BENZENESULFONAMIDE; NAPHTHALENE DERIVATIVE; SULFONAMIDE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIGNAL TRANSDUCTION;

CALCINEURIN; IMMUNOLOGIC FACTORS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; NAPHTHALENES; NFATC TRANSCRIPTION FACTORS; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 34548796003     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02993966     Document Type: Article

References (29)

1. Accerly, TSAR program (Ver.3.2); Oxford Molecular Limited, U.S.A (1999).
2. Aharoni, R., Eilam, R., Domev, H., Labunskay, G., Sela, M., and Arnon, R., The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. USA., 102, 19045-19050 (2005).
3. Albert, R., Hinterding, K., Brinkmann, V., Guerini, D., Muller-Hartwieg, C., Knecht, H., Simeon, C., Streiff, M., Wager, T., Welzenbach, K., Zecri, F., Zollinger, M., Cooke, N., and Francotte, E., Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer. J. Med. Chem., 48, 5373-5377 (2005).
4. Alvarez-Mon, M., Miravitlles, M., Morera, J., Callol, L., and Alvarez-Sala, J. L., Treatment with the Immunomodulator AM3 Improves the Health-Related Quality of Life of Patients with COPD. Chest., 127, 1212-1218 (2005).
5. Chavez-Rueda, K., Hernandez, J., Zenteno, E., Leanos-Miranda, A., Legorreta-Haquet, M. V., and Blanco-Favela, F., Identification of prolactin as a novel immunomodulator on the expression of co-stimulatory molecules and cytokine secretions on T and B human lymphocytes. Clin. Immunol., 116. 182-191 (2005).
6. Chen, J., Vista, B. P., Wiggert, B., Chan, C.C., and Gery, I., The Immunomodulator Vasoactive Instinal Peptide (VIP) does not affect Experimental Autoimmune Uveitis (EAU) in B10.RIII Mice. Ocular Immunol. Inflam., 13, 13-17 (2005).
7. Chiba, K., FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine1-phosphate receptors. Parmacol. Ther., 108. 308-319 (2005).
8. Dewar, M. J. S., Zoebisch, E. G., Healy, E. F., and Stewart, J. J. P., Development and use of quantum mechanical molecular models. 76. AM1: New general purpose quantum mechanical molecular model. J. Am. Chem. Soc., 107, 3902-3909 (1985).
9. Giamarellos-Bourboulis, E. J., Antonopoulou, A., Raftogiannis, M., Koutoukas, P., Tsaganos, T., Tziortzioti, V., Panagou, C., Adamis, T., and Giamarellou, H., Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa BMC Infect. Dis., 6, 31-41 (2006).
10. Giamarellos-Bourboulis, E. J., Tziortzioti, V., Koutoukas, P., Baziaka, F., Raftogiannis, M., Antonopoulou, A., Adamis, T., Sabracos, L., and Giamarellou, H., Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother., 57, 937-944 (2006).
11. Hansch, C. and Leo, A., In Exploring QSAR: Fundamentals and Applications in Chemistry and Biology. ACS Professional Reference Book. ACS, Washington. DC. (1995).
12. Heritage, T. W. and Lowis, D. R., Molecular hologram QSAR. Ch. 14., In Rational Drug Design. ACS Symposium Series 719, ACS, Washington. DC. 212 (1999).
13. Karelson, M., Lobanov, V. S., and Katritzky, A. R., Quantum-Chemical Descriptors in QSAR/QSPR Studies. Chem. Rev., 96, 1027-1044 (1996).
14. Kubinyi, H., QSAR: In Hansch Analysis and related Approaches. Chap. 4. VCH. Weinheim (1993).
15. Lowis, D. R., In HQSAR. A new highly prediction QSAR technique. Tripos Technical Notes, Vol. 1., No. 5 (1997).
16. Mukherjee, A. B. and Miele, L., In Chemical and Structural Approaches to Rational Drug Design; Weiner, D. B.; Williams, W. V. ed.; CRC Press, London. Chap. 9, (1995).
17. Myung, P. K., Park, K. Y., and Sung, N. D., CoMFA and CoMSIA on the Inhibition of Calcineurin-NFAT signaling by blocking protein-protein interaction with N-(4-oxo-1-(4H)-naphthalenylidene) benzenesulfonamide derivatives. Bull. Korean Chem. Soc., 26, 1941-1945 (2005).
18. Noda, K., Ohashi, Y., Sugimori, H., Ozaki, M., Niibe, H., Ogita, S., Kohno, I., Hasegawa, K., Kikuchi, Y., Takegawa, Y., Fuji, S., Tanaka, K., Ochiai, K., Kita, M., and Fujiwara, K., Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: Treatment with immunomodulator, more is not better. Gynecol. Oncol., 101, 455-463 (2006).
19. Okun, E., Saida, H., Albeck, M., Sredni, B., and Avtalion, R. R., Upregulation of carp GDNF mRNA by the immunomodulator AS101. Dev. Comp. Immunol., 30, 441-446 (2006).
20. Petrunov. B., Marinova, S., Markova, R., Nenkov. P., Nikolaeva, S., Nikolova, M., Taskov. H., and Cvetanov, J., Cellular and humoral systemic and mucosal immune responses stimulated in volunteers by an oral polybacterial immunomodulator "Dentavax". Int. Immunopharmacol., 6, 1181-1193 (2006).
21. Roehrl, M. H., Kang, S., Aramburu, J., Wagner, G., Rao, A., and Hogan, P, G., Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc. Natl. Acad. Sci. U.S.A.,101, 7544-7559 (2004).
22. Royaee, A. B., Hammamieh, R., Mendis, C., Das, R., Jett, M., and Yang, D. C., Induction of immunomodulator transcriptional responses by cholera toxin. Mol. Immunol., 43, 1020-1028 (2006).
23. Sybyl (Ver. 7.1), Tripos Associates, Inc., 1699 S. Hanley Rd., Suite 303, St. Louis, MO. 63144-2913, U.S.A.
24. Takahashi, M., Shimizu, H., Murakami, T., Enosawa, S., Suzuki, C., Takeno, Y., Hakamata, Y., Kudou, S., Izawa, S., Yasue, T., and Kobayashi, E., A novel immunomodulator KRP-203 combined with cyclosporine prolonged graft survival and abrogated transplant vasculopathy in rat heart allografts. Transplant. Proc., 37, 143-145 (2005).
25. Tolle, M., Levkau, B., Keul, P., Brinkmann, V., Giebing, G., Schonfelder, G., Schafers, M., Lipinski, K. W., Jankowski, J., Jankowski, V., Chun, J., Zidek, W., and Giet, M., Immunomodulator FTY720 Induces eNOS-Dependent Arterial Vasodilatation via the Lysophospholipid Receptor S1P3. Circ. Res., 96, 913-920 (2005).
26. Tong, W., Lowis, D. R., Perkins, R., Chen, Y., Welsh, W. j., Goddette, D. W., Heritage, T. W., and Sheehan, D. M., Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J. Chem. Inf. Comput. Sci., 38, 669-677 (1998).
27. Tuvesson, H., Hallin, I., Persson, R., Sparre, B., Gunnarsson, P. O., and Seidegard, Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metabolism and Disposition., 33, 866-872 (2005).
28. Uygur, D., Aytan, H., Zergeroglu, S., and Batioglu, S., Leflunomide-an Immunomodulator-Induces Regression of Enfomtrial Explants in a Rat Model of Endometriosis. J. Soc. Gynecol. Investig., 13, 378-383 (2006).
29. Wold, S., Sjostrom, M., Eriksson, L., and Eriksson, L., Chemom., PLS-regression: a basic tool of chemometrics. Intell. Lab. Syst., 58, 109-130 (2001).